Elizabeth A. Brem MD

picture of Elizabeth A. Brem

Assistant Clinical Professor, Division of Hematology/Oncology, Medicine
School of Medicine


B.S., Canisius College, 2006, Biochemistry
M.D., SUNY Buffalo School of Medicine, 2010

ORCiD: 0000-0002-3265-9841

Phone: (714) 456-5164
Fax: (714) 456-2242
Email: ebrem@uci.edu

University of California, Irvine
200 S. Manchester Ave.
Suite 400, Room 452
Mail Code: 4061
Orange, CA 92868
Research Interests
lymphoma, Bcl2 family, apoptosis
URLs
Awards and Honors
ASH Trainee Research Award 05/2012
ASH Abstract Achievement Award 12/2013
AACR/ASCO Methods in Clinical Cancer Research Workshop (Vail, CO) 07/2015
UC Irvine American Cancer Society Seed Grant Award 09/2016
Society of Hematologic Oncology (SoHo) Travel Grant 07/2017
National Institutes of Health (NIH) Clinical Loan Repayment Program 07/2017-9/2019
Top 20 Physician for Patient Satisfaction at UC Irvine 03/2018
LRF Lymphoma Clinical Research Mentoring Program 04/2018
SWOG Young Investigator Training Course, Hope Foundation 09/2018
Society of Hematologic Oncology (SoHo) Travel Grant 07/2019
Teacher of the Year, UCI Hematology/Oncology Fellowship 06/2021
Publications
Brem EA and O’Brien SM. Front Line Management of CLL in 2021. JCO Oncology Practice. ePub 21 July 2021.
 
Morrissette K, Bridwell R, Lentz S, Brem E, Gutierrez KO, Singh M, Koyfman A, Long B. Hemophagocytic Lymphohistiocytosis in the Emergency Department: Recognizing and Evaluating a Hidden Threat. J Emerg Med. 2021 Jun;60(6):743-751
 
Long B, Targonsky E, Brém E. Just the facts: febrile neutropenia in the emergency department setting. CJEM. 2021 Jul;23(4):445-449.
 
Lehrich BM, Goshtasbi K, Abiri A, Yasaka TM, Papagiannopoulos P, Tajudeen BA, Brem EA, Kuan EC. Treatment modalities and overall survival outcomes for sinonasal extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2021 Mar;62(3):727-730.
 
Long B, Brém E, Koyfman A. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. West J Emerg Med. 2020 Apr 13;21(3):566-580.
 
Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA et al. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019 Feb 7;133(6):566-575.
 
Khan Y, Brem EA. Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly. Curr Hematol Malig Rep. 2019 Aug;14(4):228-238.
 
Robertson JJ, Brem E, and Koyfman A. The Acute Hemolytic Anemias: The Importance of Emergency Diagnosis and Management. J Emerg Med. E pub 10 April 2017.
 
Brem EA and Letai AG. BOK: Oddball of the BCL-2 Family. Trends in Cell Biology. 2016;26(6)389-90.
Brem E and Davids M. Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma? Leukemia and Lymphoma. 2014;55(12):2675-2677.
Brem E, Koyfman A, Foran M. Review of Recently Approved Alternatives to Anticoagulation with Warfarin for Emergency Clinicians. J Emerg Med. 2013;45(1):143-9.
Koyfman A, Brem E, and Chiang V. Thrombotic Thrombocytopenic Purpura. Pediatric Emergency Care. 2011;27:1085-1091.
Brem E, Thudium K, et al. Obatoclax possesses a dual Mechanism of action and potentiates the anti-tumor effects of rituximab or chemotherapy in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology. 2011;153:599-611.
Professional Societies
American Society of Hematology (ASH)
American Society of Clinical Oncology (ASCO)
American Association of Cancer Research (AACR)
Alpha Omega Alpha
University of California Hematologic Malignancies Consortium
Medical Oncology Association of Southern California (MOASC)
Southwest Oncology Group (SWOG)
Other Experience
Internal Medicine Resident
Beth Israel Deaconess Medical Center/Harvard Medical School 2010—2013

Hematology/Oncology Fellow
Beth Israel Deaconess Medical Center/Harvard Medical School 2013—2016

Research Center
Chao Family Comprehensive Cancer Center
Last updated
10/15/2021